Article Text

Download PDFPDF
Systematic review
There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk
  1. Lokpal Bhatia,
  2. Christopher D Byrne
  1. The Institute of Developmental Sciences, University of Southampton, Southampton, UK
  1. Correspondence to Christopher D Byrne
    The Institute of Developmental Sciences (IDS Building), University of Southampton, MP 887, Southampton General Hospital, Tremona Rd, Southampton SO16 6YD, UK; cdtb{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:

Statins are one of the most widely used drug classes, with approximately 50 million prescriptions dispensed in England alone in 2008. Their efficacy and safety in significantly reducing cardiovascular events in moderate-to-high-risk patients has been well documented, both in primary and secondary prevention.1 Commonly reported side-effects include muscle aches and increases in liver enzymes, but, in general, statins are well tolerated with a low incidence of side-effects. However, the recent collaborative meta-analysis of 13 major placebo-controlled statin trials by Sattar and colleagues reports a 9% increased risk for incident diabetes over 4 years (OR 1.09; 95% CI 1.02-1-17) in patients randomised to statins compared to those assigned to placebo. Heterogeneity between trials was low (I2=11%), suggesting that this risk appears to be a true class effect, despite known differences in lipophilicity and metabolic clearance pathways between individual statin drugs.

Although these findings are of concern, it is worth pointing out that all meta-analyses have inherent limitations. Importantly, as …

View Full Text


  • Competing interests CDB has receiving funding in the form of an Independent Research Grant from Pfizer.